Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19/BCMA CAR T-cells”

86 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 86 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07324889
What this trial is testing

An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

Who this might be right for
Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
Yihao Wang 24
Early research (Phase 1)Looking for participantsNCT06349343
What this trial is testing

CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 20
Early research (Phase 1)Looking for participantsNCT06733610
What this trial is testing

CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.

Who this might be right for
Autoimmune Hemolytic AnemiaCD19/BCMA CAR T-cellsUniversal Allogeneic CAR T-cells
Institute of Hematology & Blood Diseases Hospital, China 15
Early research (Phase 1)Not Yet RecruitingNCT07114432
What this trial is testing

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

Who this might be right for
Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM)
Tianjin Medical University Cancer Institute and Hospital 19
Early research (Phase 1)WithdrawnNCT04877080
What this trial is testing

CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL

Who this might be right for
B-cell Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Not applicableLooking for participantsNCT06503224
What this trial is testing

An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
The First Affiliated Hospital of University of Science and Technology of China 18
Testing effectiveness (Phase 2)Looking for participantsNCT05850234
What this trial is testing

GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/ Refractory Multiple Myeloma
AstraZeneca 80
Testing effectiveness (Phase 2)Looking for participantsNCT06428188
What this trial is testing

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

Who this might be right for
Autoimmune DiseasesSystemic Lupus ErythematosusSystemic Lupus Erythematosus Acute+1 more
Essen Biotech 60
Early research (Phase 1)WithdrawnNCT05513612
What this trial is testing

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Who this might be right for
Acute Myeloid Leukemia (AML)B-cell Non-Hodgkin's Lymphoma (B-NHL)Multiple Myeloma (MM)+2 more
Shanghai Pudong Hospital
Very early researchLooking for participantsNCT06976437
What this trial is testing

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Who this might be right for
B Cell LymphomaMultiple Myeloma
YANRU WANG 21
Testing effectiveness (Phase 2)Looking for participantsNCT06897930
What this trial is testing

Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Who this might be right for
Lupus Erythematosus, Systemic
AstraZeneca 150
Very early researchNot Yet RecruitingNCT06986434
What this trial is testing

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Who this might be right for
Relapsed or Refractory Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences 20
Early research (Phase 1)Looking for participantsNCT07315087
What this trial is testing

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Who this might be right for
SLE - Systemic Lupus ErythematosusSSc-Systemic SclerosisIIM- Idiopathic Inflammatory Myopathies+3 more
Institute of Hematology & Blood Diseases Hospital, China 12
Early research (Phase 1)UnknownNCT03706547
What this trial is testing

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma Progression
Peng Liu 20
Very early researchLooking for participantsNCT07203404
What this trial is testing

Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

Who this might be right for
SLELNANCA Associated Vasculitis+5 more
Nanjing Bioheng Biotech Co., Ltd. 84
Very early researchLooking for participantsNCT07261345
What this trial is testing

Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease

Who this might be right for
Graves' Disease
Shanghai Zhongshan Hospital 4
Very early researchLooking for participantsNCT06785519
What this trial is testing

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

Who this might be right for
Lupus Nephritis
He Huang 9
Very early researchLooking for participantsNCT06732232
What this trial is testing

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Who this might be right for
RelapsedRefractoryMultiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd 12
Not applicableLooking for participantsNCT07359014
What this trial is testing

Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapse Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University 25
Very early researchLooking for participantsNCT07241468
What this trial is testing

An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease

Who this might be right for
Relapsed/Refractory Immune NephropathyRelapsed/Refractory Immune-mediated Kidney Disease
Changhai Hospital 36
Load More Results